Summary
Eli Lilly and Company reported strong revenue growth of 9% for the quarter ended June 30, 2016, reaching $5.4 billion, and 7% for the six-month period, totaling $10.3 billion. This growth was primarily driven by increased volume in key products such as Trulicity®, Erbitux®, and Humalog®, as well as strong performance in the U.S. market. Net income saw a significant increase of 24% for the quarter to $747.7 million, and a 5% increase for the six-month period to $1.19 billion. Earnings per share (EPS) also demonstrated positive momentum, up 27% for the quarter and 6% for the six-month period, benefiting from a higher gross margin and a reduction in prior-year charges like acquired in-process R&D and debt repurchase expenses. Despite the positive financial performance, investors should note potential headwinds. The company faces ongoing patent expirations and the increasing threat of generic competition for key products like Alimta®, Zyprexa®, Strattera®, and Cialis®, which are expected to materially impact future revenues. Additionally, a significant charge related to the Venezuelan financial crisis and ongoing legal and patent litigations for products like Alimta and Effient present continued risks. Management reaffirmed its full-year 2016 financial guidance, expecting EPS between $2.68 and $2.78 and revenue between $20.6 billion and $21.1 billion, indicating confidence in continued performance.
Financial Highlights
53 data points| Revenue | $5.40B |
| Cost of Revenue | $1.47B |
| Gross Profit | $3.94B |
| R&D Expenses | $1.34B |
| SG&A Expenses | $1.62B |
| Operating Expenses | $2.96B |
| Interest Expense | $43.20M |
| Net Income | $747.70M |
| EPS (Basic) | $0.71 |
| EPS (Diluted) | $0.71 |
| Shares Outstanding (Basic) | 1.06B |
| Shares Outstanding (Diluted) | 1.06B |
Key Highlights
- 1Revenue increased by 9% year-over-year to $5.4 billion for the quarter and 7% to $10.3 billion for the six-month period, driven by volume growth in key products.
- 2Net income rose by 24% for the quarter to $747.7 million and 5% for the six-month period to $1.19 billion.
- 3Diluted Earnings Per Share (EPS) increased by 27% for the quarter to $0.71 and 6% for the six-month period to $1.12.
- 4Gross margin as a percentage of revenue slightly decreased to 72.9% for both periods compared to the prior year, primarily due to foreign exchange impacts and the transfer of Erbitux commercialization rights.
- 5Research and Development (R&D) expenses increased by 14% for the quarter and 16% for the six-month period, reflecting higher late-stage clinical development costs.
- 6The company reaffirmed its full-year 2016 financial guidance, expecting EPS between $2.68 and $2.78 and revenue between $20.6 billion and $21.1 billion.
- 7Significant legal and patent challenges for key products like Alimta and Effient, along with upcoming patent expirations for Strattera and Cialis, pose potential risks to future revenue.